Amid growing global concern that existing and proposed incentives for antibiotic development will fall short of meeting public health needs, FDA is poised to approve as many as four novel antibiotics this year – including one candidate for Gram-negative bacterial infections, an especially high priority area.
While the two new molecular entity antibiotics recently approved – Durata Therapeutics Inc.’s second-generation lipoglycopeptide Dalvance (dalbavancin) and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?